[1] Bulsari K,Falhammar H.Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency[J].Endocrine,2017,55(1):19-36. [2] Matallana-Rhoades AM,Corredor-Castro JD,Bonilla-Escobar FJ,et al.Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency: description of a new mutation,R384X[J].Colomb Med (Cali),2016,47(3):172-175. [3] Belkina NV,Lisurek M,Ivanov AS,et al.Modelling of three-dimensional structures of cytochromes P450 11B1 and 11B2[J].Inorg Biochem,2001,87(4):197-207. [4] Yuan X,Lu L,Chen S,et al.A Chinese patient with 11β-hydroxylase deficiency due to novel compound heterozygous mutation in CYP11B1 gene: a case report[J].BMC Endocr Disord,2018,18(1):68. [5] Wang D,Wang J,Tong T,et al.Non-classical 11β-hydroxylase deficiency caused by compound heterozygous mutations: a case study and literature review[J].Ovarian Res,2018,11(1):82. [6] Khattab A,Haider S,Kumar A,et al.Clinical,genetic,and structural basis of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency[J].Proc Natl Acad Sci U S A,2017,114(10):1933-1940. [7] Guven A,Nurcan Cebeci A,Hancili S.Gonadotropin releasing hormone analog treatment in children with congenital adrenal hyperplasia complicated by central precocious puberty[J].Hormones (Athens),2015,14(2):265-271. [8] Goedegebuure WJ,Hokken-Koelega ACS.Aromatase inhibitor as treatment for severely advanced bone age in congenital adrenal hyperplasia: a case report[J].Horm Res Paediatr,2019,92(3):209-213.
2022, Vol. 28 
冀公网安备13080202000677号